JP2007508272A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508272A5
JP2007508272A5 JP2006530155A JP2006530155A JP2007508272A5 JP 2007508272 A5 JP2007508272 A5 JP 2007508272A5 JP 2006530155 A JP2006530155 A JP 2006530155A JP 2006530155 A JP2006530155 A JP 2006530155A JP 2007508272 A5 JP2007508272 A5 JP 2007508272A5
Authority
JP
Japan
Prior art keywords
virus
spp
polypeptide
combined preparation
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006530155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508272A (ja
Filing date
Publication date
Priority claimed from GBGB0323965.4A external-priority patent/GB0323965D0/en
Application filed filed Critical
Publication of JP2007508272A publication Critical patent/JP2007508272A/ja
Publication of JP2007508272A5 publication Critical patent/JP2007508272A5/ja
Pending legal-status Critical Current

Links

JP2006530155A 2003-10-13 2004-10-11 インターロイキン18およびサポニンアジュバント系を含むワクチン組成物 Pending JP2007508272A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0323965.4A GB0323965D0 (en) 2003-10-13 2003-10-13 Immunogenic compositions
PCT/EP2004/011620 WO2005039634A1 (en) 2003-10-13 2004-10-11 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system

Publications (2)

Publication Number Publication Date
JP2007508272A JP2007508272A (ja) 2007-04-05
JP2007508272A5 true JP2007508272A5 (enExample) 2007-07-26

Family

ID=29559205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530155A Pending JP2007508272A (ja) 2003-10-13 2004-10-11 インターロイキン18およびサポニンアジュバント系を含むワクチン組成物

Country Status (17)

Country Link
US (1) US20070212329A1 (enExample)
EP (1) EP1687025A1 (enExample)
JP (1) JP2007508272A (enExample)
KR (1) KR20070054136A (enExample)
CN (1) CN1889977A (enExample)
AU (1) AU2004283457A1 (enExample)
BR (1) BRPI0415304A (enExample)
CA (1) CA2541695A1 (enExample)
CO (1) CO5700790A2 (enExample)
GB (1) GB0323965D0 (enExample)
IL (1) IL174544A0 (enExample)
IS (1) IS8374A (enExample)
MA (1) MA28149A1 (enExample)
NO (1) NO20061912L (enExample)
RU (1) RU2006111847A (enExample)
WO (1) WO2005039634A1 (enExample)
ZA (1) ZA200602950B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
US7727561B2 (en) 2001-08-31 2010-06-01 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7524824B2 (en) * 2003-09-04 2009-04-28 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
SG172476A1 (en) * 2002-08-12 2011-07-28 Dynavax Tech Corp Immunomodulatory compositions comprising a cationic condensing agent, an immunostimulatory compound comprising 5'-cg-3', an a non ionic detergent
US7514412B2 (en) * 2003-10-09 2009-04-07 Pacific Arrow Limited Anticancer biangeloyl saponins
US8614197B2 (en) * 2003-10-09 2013-12-24 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
US7488753B2 (en) * 2003-10-09 2009-02-10 Pacific Arrow Limited Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof
JP4815558B2 (ja) * 2003-10-09 2011-11-16 パシフィック アロー リミテッド Xanthocerassorbifolia抽出物を含む組成物、該抽出物から単離された化合物、それらを調製する方法、およびそれらの使用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
DE102004022200B4 (de) 2004-05-05 2006-07-20 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
US8735558B2 (en) * 2005-02-14 2014-05-27 Pacific Arrow Limited Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
US9382285B2 (en) 2004-09-07 2016-07-05 Pacific Arrow Limited Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells
US8586719B2 (en) * 2005-04-27 2013-11-19 Pacific Arrow Limited Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
DE102006008023B4 (de) 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets
CA2662932C (en) 2006-09-08 2017-06-06 Actinium Pharmaceuticals, Inc. Method for the purification of radium from different sources
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US8741313B2 (en) 2008-01-11 2014-06-03 Emory University Polypeptide vaccine and vaccination strategy against mycobacterium
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
CN102076358B (zh) * 2008-06-27 2016-08-17 硕腾有限责任公司 新颖的佐剂组合物
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
WO2010147268A1 (ko) * 2009-06-19 2010-12-23 아이진 주식회사 자궁경부암 백신
US20120277308A1 (en) 2010-07-16 2012-11-01 Pacific Arrow Limited compounds for treating cancer and other diseases
US9499577B2 (en) 2009-07-16 2016-11-22 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
US9434677B2 (en) 2009-07-16 2016-09-06 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
HRP20161608T1 (hr) * 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni
BR112012030337B1 (pt) * 2010-05-28 2021-04-27 Coley Pharmaceutical Group, Inc Vacina compreendendo um ou mais oligonucleotídeo(s) de cpg isolado(s) ou um agonista de tlr e colesterol, e uso da mesma
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
RU2482866C2 (ru) * 2010-10-07 2013-05-27 Общество с ограниченной ответственностью "Аллоферон" Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина-18
IN2014CN02581A (enExample) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
GB201205361D0 (en) * 2012-03-27 2012-05-09 Univ Nottingham Trent Breast cancer assay
EP2941436B1 (en) * 2013-01-04 2020-12-02 OBI Pharma, Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
CN106794263A (zh) * 2014-10-01 2017-05-31 宾夕法尼亚大学理事会 具有抗原和作为佐剂的白细胞介素‑21的疫苗
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
GB201522329D0 (en) * 2015-12-17 2016-02-03 Glaxosmithkline Biolog S A And Inst Nat De La Sante Et De La Rech Medicale Inserm And Université Pie Use of adjuvants for the prevention and/or treatment of autoimmune diseases
US10874733B2 (en) 2016-10-31 2020-12-29 Eyegene Inc. Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CN107952069A (zh) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 重组疫苗及其应用
EP3669890A1 (en) * 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
TR201907085A2 (tr) 2019-05-10 2020-11-23 Univ Yeditepe Parazi̇tleri̇n ve parazi̇tlerden elde edi̇len ekstraselüler vezi̇külleri̇n kanser tedavi̇si̇nde kullanimi
WO2021048081A1 (en) * 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
CN112972671B (zh) * 2019-12-13 2024-04-19 远大赛威信生命科学(南京)有限公司 药物组合物及其用途
WO2022034555A1 (en) * 2020-08-13 2022-02-17 Janssen Biopharma, Inc. Polynucleotide constructs and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ253137A (en) * 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6355256B1 (en) * 1994-09-30 2002-03-12 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
WO1999056775A1 (en) * 1998-05-07 1999-11-11 Akzo Nobel N.V. Use of interleukin-18 as vaccine adjuvant
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
AU2001233212A1 (en) * 2000-02-02 2001-08-14 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using

Similar Documents

Publication Publication Date Title
JP2007508272A5 (enExample)
RU2006111847A (ru) Вакцинные композиции, содержащие интерлейкин 18 и сапониновую адъювантную систему
JP2007508273A5 (enExample)
RU2006111849A (ru) Иммуногенные композиции
Lacaille-Dubois Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review
Correa et al. Vaccines, adjuvants and key factors for mucosal immune response
ES2331952T3 (es) Fraccion de quil a con baja toxicidad y su uso.
TWI232753B (en) Adjuvant compositions comprising QS-21,3D-MPL and CpG and vaccine compositions comprising the same
Singh et al. Recent advances in vaccine adjuvants
Van Ginkel et al. Vaccines for mucosal immunity to combat emerging infectious diseases
Weinberger et al. Vaccines for the elderly
O'Hagan et al. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles
RU2004135541A (ru) Иммуногенные композиции
US20020160011A1 (en) Adjuvant compositions for vaccines
JP2004511529A (ja) 免疫刺激性オリゴヌクレオチドおよびトコールを含むアジュバント組成物
Zhang et al. Effects of astragalus polysaccharide on the immune response to foot-and-mouth disease vaccine in mice
JP2006506441A5 (enExample)
Moingeon et al. Delivery technologies for human vaccines
JP2002531521A5 (enExample)
JP5307859B2 (ja) ワクチン
Xiang et al. Promising particle-based vaccines in cancer therapy
JP2009108060A (ja) 血糖を制御するための医薬組成物及びその方法
JP2003530088A5 (enExample)
Reyes et al. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization
JP2004531540A (ja) Hiv抗原並びにhsv抗原及び/又はhpv抗原を含む多価ワクチン